Circulating tumor DNA genomics reveals potential mechanisms of resistance to BRAF-targeted therapies in BRAF-mutant metastatic non-small cell lung cancer patients.
Fiche publication
Date publication
août 2020
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie
Tous les auteurs :
Ortiz-Cuaran S, Mezquita L, Swalduz A, Aldea M, Mazieres J, Leonce C, Jovelet C, Pradines A, Avrillon V, Chumbi Flores WR, Lacroix L, Loriot Y, Westeel V, Ngo-Camus M, Tissot C, Raynaud C, Gervais R, Brain E, Monnet I, Giroux Leprieur E, Caramella C, Mahier-Aït Oukhatar C, Hoog-Labouret N, de Kievit F, Howarth K, Morris C, Green E, Friboulet L, Chabaud S, Guichou JF, Perol M, Besse B, Blay JY, Saintigny P, Planchard D
Lien Pubmed
Résumé
The limited knowledge on the molecular profile of -mutant non-small cell lung cancer (NSCLC) patients who progress under BRAF-targeted therapies (BRAF-TT) has hampered the development of subsequent therapeutic strategies for these patients. Here, we evaluated the clinical utility of ctDNA targeted sequencing to identify canonical mutations and genomic alterations potentially related to resistance to BRAF-TT, in a large cohort of mutant NSCLC patients.
Référence
Clin. Cancer Res.. 2020 Aug 28;: